Skip to main content
Allogene Therapeutics, Inc. logo

Allogene Therapeutics, Inc. — Investor Relations & Filings

Ticker · ALLO ISIN · US0197701065 US Manufacturing
Open in API
Filings indexed 523 across all filing types
Latest filing 2021-08-03 Director's Dealing
Country US United States of America
Listing US ALLO

About Allogene Therapeutics, Inc.

https://allogene.com/

Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies. The company engineers T cells from healthy donors to create "off-the-shelf" treatments for cancer and autoimmune diseases. This approach is designed to enable on-demand availability, scalability, and reliability, contrasting with autologous therapies that use a patient's own cells. Allogene's pipeline utilizes multiplex gene-engineering and gene-editing capabilities. Its key investigational programs include cemacabtagene ansegedleucel (cema-cel) for large B-cell lymphoma, ALLO-316 for clear cell renal cell carcinoma, and ALLO-329 for autoimmune disease.

Recent filings

Filing Released Lang Actions
PRIMARY DOCUMENT
Director's Dealing
2021-08-03 English
PRIMARY DOCUMENT
Director's Dealing
2021-08-03 English
8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated July 30, 2021, reporting changes in the company's board of directors. It announces the increase in the number of directors and the appointment of two new directors, including details about their compensation and indemnification agreements. There is no financial data or report content, only management and board changes. This fits the category of Board/Management Information (MANG). The document length is 5989 characters, which is sufficient for a detailed announcement rather than a brief notice. Therefore, the classification is MANG with high confidence.
2021-08-02 English
PRIMARY DOCUMENT
Director's Dealing
2021-07-16 English
PRIMARY DOCUMENT
Director's Dealing
2021-06-16 English
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated June 10, 2021, reporting the results of the 2021 Annual Meeting of Stockholders of Allogene Therapeutics, Inc. It details the voting outcomes on director elections, executive compensation advisory vote, and ratification of the independent auditor. The content focuses on the submission of matters to a vote of security holders and the official voting results. There is no detailed financial data or comprehensive report content, but rather an official announcement of voting results from the annual meeting. According to the filing definitions, this matches the category 'Declaration of Voting Results & Voting Rights Announcements (DVA)'. The document length is about 4938 characters, which is sufficient to contain the voting results and not just a brief announcement. Therefore, the classification is DVA with high confidence.
2021-06-15 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.